leisure time -WSS

leisure time

author：leisure time 2025-09-30 22:27:26 - browse：743

Joe Biden in 2016. -- first opinion coverage from STAT — President Joe Biden Elise Amendola/AP

WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few questions on how Congress might move forward with the program.

Since its launch in 2016, the federally funded cancer moonshot program has spurred thousands of scientific publications, 49 clinical trials, and more than 30 patent filings, according to a new report from the Congressional Research Service, the nonpartisan research arm of Congress.

The next phase of the cancer moonshot, according to Biden and his administration, is meant to emphasize cancer screening, prevention, and equitable treatment. The updated plan also seeks to speed progress on treatments for rare and childhood cancers, and it calls for supporting patients, survivors, and caregivers. The Advanced Research Projects Agency for Health (ARPA-H), a new agency tasked with taking big risks on biomedical and health technology, is also committing $240 million to cancer-related research and investing in new data-sharing platforms and a nationwide network for clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： 'Revelatory' study finds a smoking impact that remains after quitting

leisure time

explore

WSS

The dental labor crisis is a moment of opportunity

Medical mystery: When a cough is not just a cough

BioAge raises $170M for combination therapy with Zepbound

Cheap, fast test for Zika and dengue could cost just $1

To avoid data mishandling cases, universities eye AI and other tools

Medicare threatens to cut off funding for HCA's Mission hospital

knowledge

leisure time

focus

In Memoriam: Notable people who died in 2023

Why did Pfizer dish out millions for a Super Bowl ad?

In Memoriam: Notable people who died in 2023

Biogen Alzheimer’s drug launch off to slow start

Apple is now the first public company to be valued at $3 trillion

Vaccine advisory panel ACIP left half staffed by HHS

After affirmative action ruling, medical educators look to 'holistic review'

STAT Virtual Event: ASCO Recap, Live!

23andMe had bad news about my health. I wish a person had delivered it

How digital tools helped lower hypertension in marginalized patients

focus

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Industry veterans launch new biotech VC with $310M

Key House Republican on health care plans exit from Congress

Report captures long Covid’s disabling effects and policy challenges

Medicare threatens to cut off funding for HCA's Mission hospital

New report analyzes digital physical therapy solutions' effectiveness

focus

leisure time

explore

focus